Valve-in-valve transcatheter aortic valve implantation (viv-TAVI) in patients with degenerated, surgically implanted bioprosthetic heart valves appears to achieve high technical success rates, according to findings from an international analysis. The viv-TAVI procedure also resulted in acceptable valvular function and excellent functional improvement. However, the authors noted that viv-TAVI had a 30-day mortality rate of 17%. Vascular access complications and renal failure requiring dialysis occurred in 13% and 9% of patients, respectively.
Abstract: Journal of the American College of Cardiology: Cardiovascular Interventions, November 2011.
